These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 8607022)

  • 1. Mutant ras epitopes as targets for cancer vaccines.
    Abrams SI; Hand PH; Tsang KY; Schlom J
    Semin Oncol; 1996 Feb; 23(1):118-34. PubMed ID: 8607022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.
    Abrams SI; Khleif SN; Bergmann-Leitner ES; Kantor JA; Chung Y; Hamilton JM; Schlom J
    Cell Immunol; 1997 Dec; 182(2):137-51. PubMed ID: 9514698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses.
    Abrams SI; Stanziale SF; Lunin SD; Zaremba S; Schlom J
    Eur J Immunol; 1996 Feb; 26(2):435-43. PubMed ID: 8617315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization.
    Bristol JA; Orsini C; Lindinger P; Thalhamer J; Abrams SI
    Cell Immunol; 2000 Nov; 205(2):73-83. PubMed ID: 11104579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide-specific activation of cytolytic CD4+ T lymphocytes against tumor cells bearing mutated epitopes of K-ras p21.
    Abrams SI; Dobrzanski MJ; Wells DT; Stanziale SF; Zaremba S; Masuelli L; Kantor JA; Schlom J; Masuelle L [corrected to Masuelli L]
    Eur J Immunol; 1995 Sep; 25(9):2588-97. PubMed ID: 7589131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a human CD8+ T lymphocyte neo-epitope created by a ras codon 12 mutation which is restricted by the HLA-A2 allele.
    Bergmann-Leitner ES; Kantor JA; Shupert WL; Schlom J; Abrams SI
    Cell Immunol; 1998 Aug; 187(2):103-16. PubMed ID: 9732698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T cell recognition of transforming proteins encoded by mutated ras proto-oncogenes.
    Peace DJ; Chen W; Nelson H; Cheever MA
    J Immunol; 1991 Mar; 146(6):2059-65. PubMed ID: 2005390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T cell epitopes encompassing the mutational hot spot position 61 of p21 ras. Promiscuity in ras peptide binding to HLA.
    Gedde-Dahl T; Spurkland A; Fossum B; Wittinghofer A; Thorsby E; Gaudernack G
    Eur J Immunol; 1994 Feb; 24(2):410-4. PubMed ID: 7507844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a murine mutant Ras CD8+ CTL peptide epitope variant that possesses enhanced MHC class I binding and immunogenic properties.
    Bristol JA; Schlom J; Abrams SI
    J Immunol; 1998 Mar; 160(5):2433-41. PubMed ID: 9498787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induced by vaccination with T-helper epitopes.
    Gjertsen MK; Saeterdal I; Saebøe-Larssen S; Gaudernack G
    J Mol Med (Berl); 2003 Jan; 81(1):43-50. PubMed ID: 12545248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene-modified spontaneous Epstein-Barr virus-transformed lymphoblastoid cell lines as autologous cancer vaccines: mutated p21 ras oncogene as a model.
    Kubuschok B; Cochlovius C; Jung W; Schmits R; Trümper L; Hartmann F; Renner C; Pfreundschuh M
    Cancer Gene Ther; 2000 Sep; 7(9):1231-40. PubMed ID: 11023195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide].
    Yang B; He Y; Sun DL; Zou Y; Qin XH; Huang BH
    Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1956-60. PubMed ID: 19062734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overlapping epitopes encompassing a point mutation (12 Gly-->Arg) in p21 ras can be recognized by HLA-DR, -DP and -DQ restricted T cells.
    Fossum B; Gedde-Dahl T; Hansen T; Eriksen JA; Thorsby E; Gaudernack G
    Eur J Immunol; 1993 Oct; 23(10):2687-91. PubMed ID: 7691613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of linear and branched peptide forms (MAPs) in the induction of T helper responses to point-mutated ras immunogens.
    Schott ME; Wells DT; Schlom J; Abrams SI
    Cell Immunol; 1996 Dec; 174(2):199-209. PubMed ID: 8954620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer.
    Kubuschok B; Neumann F; Breit R; Sester M; Schormann C; Wagner C; Sester U; Hartmann F; Wagner M; Remberger K; Schilling M; Pfreundschuh M
    Clin Cancer Res; 2006 Feb; 12(4):1365-72. PubMed ID: 16489095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation.
    Gjertsen MK; Bjorheim J; Saeterdal I; Myklebust J; Gaudernack G
    Int J Cancer; 1997 Sep; 72(5):784-90. PubMed ID: 9311595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence, immune specificity, and functional ability of murine mutant ras epitope-specific CD4(+) and CD8(+) T lymphocytes following in vivo adoptive transfer.
    Bristol JA; Schlom J; Abrams SI
    Cell Immunol; 1999 May; 194(1):78-89. PubMed ID: 10357883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
    May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of MHC class I antigens in oncogenic transformants: association with decreased recognition by cytotoxic T lymphocytes.
    Seliger B; Harders C; Wollscheid U; Staege MS; Reske-Kunz AB; Huber C
    Exp Hematol; 1996 Sep; 24(11):1275-9. PubMed ID: 8862437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Codon optimized expression of HPV 16 E6 renders target cells susceptible to E6-specific CTL recognition.
    Samorski R; Gissmann L; Osen W
    Immunol Lett; 2006 Sep; 107(1):41-9. PubMed ID: 16949679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.